论文部分内容阅读
目的:研究壮骨镇痛胶囊对高转移人乳腺癌MDA-MB-231细胞骨架蛋白p-Ezrin、F-actin和β-tubulin表达水平的影响。方法:RT-PCR法检测不同浓度壮骨镇痛胶囊含药血浆对MDA-MB-231细胞p-Ezrin基因转录水平的影响,免疫细胞化学法检测其对MDA-MB-231细胞p-Ezrin、F-actin和β-tubulin翻译水平的影响。结果:5.0%、1.25%壮骨镇痛胶囊含药血浆显著抑制了MDA-MB-231细胞p-Ezrin基因的转录(P值分别为0.000和0.042)和翻译(P值分别为0.000和0.001),抑制了F-actin(5.0%和1.25%的P值分别为0.003和0.044)和β-tubulin(5.0%和1.25%的P值均为0.000)蛋白表达;0.63%壮骨镇痛胶囊含药血浆反而促进了p-Ezrin基因的转录(P=0.000),但对p-Ezrin、F-actin和β-tubulin蛋白表达无显著影响。结论:壮骨镇痛胶囊可通过抑制乳腺癌MDA-MB-231细胞p-Ezrin、F-actin和β-tubulin蛋白表达来降低细胞的迁移能力,并且该作用与浓度密切相关。
Objective: To study the effect of Zhuangguizhuangtong capsule on the expression of skeletal proteins p-Ezrin, F-actin and β-tubulin in highly metastatic human breast cancer MDA-MB-231 cells. Methods: RT-PCR was used to detect the effect of different concentrations of Zhuangguizeng Capsule on the transcription of p-Ezrin gene in MDA-MB-231 cells. The expression of p-Ezrin, Effects of F-actin and β-tubulin translation levels. Results: 5.0% and 1.25% of the drug-containing plasma of Zhuangguizhu Capsule significantly inhibited the transcription of p-Ezrin gene (P = 0.000 and 0.042, respectively) and translation (P = 0.000 and 0.001) , Inhibited the expression of F-actin (0.003 and 0.044 for 5.0% and 1.25% P values and 0.000% for 5.0% and 1.25% P values, respectively); and 0.63% Plasma instead promoted p-Ezrin gene transcription (P = 0.000), but had no significant effect on the expression of p-Ezrin, F-actin and β-tubulin. Conclusion: Zhuangguizhuang Capsule can reduce the cell migration ability by inhibiting the expression of p-Ezrin, F-actin and β-tubulin in breast cancer MDA-MB-231 cells, and the effect is closely related with the concentration.